BR112012003759A2 - "anticorpo anti-cmet e seu uso para a detecção e o diagnóstico de câncer." - Google Patents

"anticorpo anti-cmet e seu uso para a detecção e o diagnóstico de câncer."

Info

Publication number
BR112012003759A2
BR112012003759A2 BR112012003759A BR112012003759A BR112012003759A2 BR 112012003759 A2 BR112012003759 A2 BR 112012003759A2 BR 112012003759 A BR112012003759 A BR 112012003759A BR 112012003759 A BR112012003759 A BR 112012003759A BR 112012003759 A2 BR112012003759 A2 BR 112012003759A2
Authority
BR
Brazil
Prior art keywords
diagnosis
cancer detection
cmet antibody
cmet
antibody
Prior art date
Application number
BR112012003759A
Other languages
English (en)
Portuguese (pt)
Inventor
Jouhanneaud Alexandra
Goetsch Liliane
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of BR112012003759A2 publication Critical patent/BR112012003759A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BR112012003759A 2009-08-21 2010-08-23 "anticorpo anti-cmet e seu uso para a detecção e o diagnóstico de câncer." BR112012003759A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23586409P 2009-08-21 2009-08-21
EP09305777A EP2287197A1 (en) 2009-08-21 2009-08-21 Anti-cMET antibody and its use for the detection and the diagnosis of cancer
US34800510P 2010-05-25 2010-05-25
PCT/EP2010/062271 WO2011020925A1 (en) 2009-08-21 2010-08-23 Anti-cmet antibody and its use for the detection and the diagnosis of cancer

Publications (1)

Publication Number Publication Date
BR112012003759A2 true BR112012003759A2 (pt) 2017-07-11

Family

ID=41571045

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012003759A BR112012003759A2 (pt) 2009-08-21 2010-08-23 "anticorpo anti-cmet e seu uso para a detecção e o diagnóstico de câncer."

Country Status (19)

Country Link
US (2) US8673302B2 (https=)
EP (2) EP2287197A1 (https=)
JP (1) JP5951486B2 (https=)
KR (1) KR20120051734A (https=)
CN (1) CN102639564B (https=)
AR (1) AR077901A1 (https=)
AU (1) AU2010284944B2 (https=)
BR (1) BR112012003759A2 (https=)
CA (1) CA2769427C (https=)
ES (1) ES2692522T3 (https=)
IL (1) IL218202A (https=)
IN (1) IN2012DN01322A (https=)
MX (1) MX2012002139A (https=)
NZ (2) NZ700437A (https=)
RU (1) RU2582265C2 (https=)
SG (1) SG178339A1 (https=)
TW (1) TW201111781A (https=)
WO (1) WO2011020925A1 (https=)
ZA (1) ZA201202076B (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
KR20130103734A (ko) 2010-08-31 2013-09-24 제넨테크, 인크. 바이오마커 및 치료 방법
KR101444837B1 (ko) 2011-06-03 2014-09-30 한국생명공학연구원 ＨＧＦ 활성을 가지는 ｃ-Ｍｅｔ에 대한 인간항체 및 이의 용도
AU2012312515A1 (en) 2011-09-19 2014-03-13 Genentech, Inc. Combination treatments comprising c-met antagonists and B-raf antagonists
KR20130036993A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
EP2782932A1 (en) 2011-11-21 2014-10-01 F.Hoffmann-La Roche Ag Purification of anti-c-met antibodies
ES2736999T3 (es) * 2011-11-21 2020-01-09 Taivex Therapeutics Corp Biomarcadores para cánceres que responden a moduladores de la actividad de Hec1
GB201121914D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
JP6129956B2 (ja) * 2012-05-09 2017-05-17 イーライ リリー アンド カンパニー 抗ｃ−Ｍｅｔ抗体
WO2013192594A2 (en) * 2012-06-21 2013-12-27 Sorrento Therapeutics Inc. Antigen binding proteins that bind c-met
EP2958592A1 (en) 2013-02-22 2015-12-30 F. Hoffmann-La Roche AG Methods of treating cancer and preventing drug resistance
US10214593B2 (en) 2013-04-02 2019-02-26 Samsung Electronics Co., Ltd. Anti-idiotype antibody against anti-c-MET antibody
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
WO2015031626A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
WO2015031614A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
WO2015032695A1 (en) * 2013-09-09 2015-03-12 Ventana Medical Systems, Inc. Scoring method for mesothelin protein expression
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
KR20170005016A (ko) 2014-05-23 2017-01-11 제넨테크, 인크. MiT 바이오마커 및 그의 사용 방법
JP6864953B2 (ja) 2014-12-09 2021-04-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ａｘｌに対するヒトモノクローナル抗体
EP3253791A1 (en) * 2015-02-03 2017-12-13 INSERM - Institut National de la Santé et de la Recherche Médicale Anti-rho gtpase conformational single domain antibodies and uses thereof
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
MX382582B (es) * 2015-03-18 2025-03-13 Seagen Inc Anticuerpos contra cúmulo de diferenciación 48 (cd48) y sus conjugados.
JP6669882B2 (ja) * 2016-02-05 2020-03-18 ヘリックスミス カンパニー リミテッド 抗−ｃ−ＭＥＴ抗体及びその用途
RS61659B1 (sr) 2016-05-17 2021-04-29 Abbvie Biotherapeutics Inc Konjugati antitelo lek anti-cmet i metode za njihovu upotrebu
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
RU2735918C2 (ru) * 2018-06-07 2020-11-10 Общество с ограниченной ответственностью "ДЖЕЙВИС ДИАГНОСТИКС" Набор реагентов для выявления маркера эпителиальных карцином
JP7332194B2 (ja) * 2018-06-29 2023-08-23 スーチョウ スマートヌクライド バイオファーマシューティカル カンパニー リミテッド Ｐｄ－ｌ１結合ポリペプチドおよびそれらの使用
KR102396194B1 (ko) * 2018-12-07 2022-05-10 서울대학교 산학협력단 항 c-Met 아고니스트 항체 및 이의 용도
EP3980783A4 (en) * 2019-06-06 2023-09-13 Apollomics Inc. (Hangzhou) Method for treating cancer patients using c-met inhibitor
US11896682B2 (en) 2019-09-16 2024-02-13 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof
EP4129335A4 (en) 2020-09-01 2024-04-24 RemeGen Co., Ltd. ANTI C-MET DRUG-ANTIBODY CONJUGATE AND ITS APPLICATIONS
JP2023541011A (ja) * 2020-09-08 2023-09-27 イデアヤ、バイオサイエンシズ、インコーポレイテッド 医薬組み合わせおよび腫瘍治療
AU2023283550A1 (en) * 2022-06-09 2024-11-21 Santa Ana Bio, Inc. Antibodies targeting c-kit and/or siglec and uses thereof
CA3263050A1 (en) 2022-07-30 2024-02-08 Pinetree Therapeutics, Inc. Compositions for targeted lysosomal degradation and their methods of use
IL326548A (en) * 2023-08-14 2026-04-01 Minghui Pharmaceutical Hangzhou Ltd Nanoantibody against C-MET and its use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
AU2002357388A1 (en) * 2001-12-27 2003-07-24 The United States Of America, As Represented By The Department Of Veterans Affairs Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
WO2007056523A2 (en) * 2005-11-08 2007-05-18 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for diagnosing and monitoring the progression of cancer
CA2638889C (en) * 2006-02-06 2015-06-02 Metheresis Translational Research S.A. Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US7892770B2 (en) * 2007-08-24 2011-02-22 Van Andel Research Institute Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
AR074439A1 (es) * 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer

Also Published As

Publication number Publication date
NZ598194A (en) 2015-05-29
CN102639564A (zh) 2012-08-15
US8673302B2 (en) 2014-03-18
AU2010284944B2 (en) 2016-01-28
JP5951486B2 (ja) 2016-07-13
KR20120051734A (ko) 2012-05-22
US20140295452A1 (en) 2014-10-02
WO2011020925A1 (en) 2011-02-24
IN2012DN01322A (https=) 2015-06-05
SG178339A1 (en) 2012-03-29
AU2010284944A1 (en) 2012-03-08
ES2692522T3 (es) 2018-12-04
CA2769427C (en) 2020-03-10
CN102639564B (zh) 2015-01-07
EP2287197A1 (en) 2011-02-23
ZA201202076B (en) 2012-11-28
AR077901A1 (es) 2011-09-28
JP2013502213A (ja) 2013-01-24
RU2582265C2 (ru) 2016-04-20
NZ700437A (en) 2016-04-29
EP2467402A1 (en) 2012-06-27
IL218202A0 (en) 2012-04-30
IL218202A (en) 2017-07-31
MX2012002139A (es) 2012-03-07
US20120149031A1 (en) 2012-06-14
RU2012109004A (ru) 2013-09-27
CA2769427A1 (en) 2011-02-24
TW201111781A (en) 2011-04-01
EP2467402B1 (en) 2018-08-01

Similar Documents

Publication Publication Date Title
BR112012003759A2 (pt) "anticorpo anti-cmet e seu uso para a detecção e o diagnóstico de câncer."
HUS2100038I1 (hu) Anti-CD20 antitest készítmények
PT2376535T (pt) Anticorpos anti-pd-l1 e a sua utilização para a melhoria do funcionamento das células t
BRPI0923231A2 (pt) anticorpo anti-cmet.
BRPI1008692A2 (pt) moléculas de anticorpos tendo especificidade para ox40 humano.
BRPI0906478A2 (pt) anticorpo anti-nr10 e uso do mesmo
BRPI1016234A2 (pt) dispositivo aplicador para uso médico e/ou cosmético.
BRPI1008740A2 (pt) Proteínas pesticidas e métodos para seu uso.
BRPI1010621A2 (pt) derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso
PL2411408T3 (pl) Rozpuszczalne przeciwciała "tylko cieżkołańcuchowe"
BRPI0816919A2 (pt) Redução de infecções concomitantes em porcos pelo uso de antígeno pcv2.
IL235261B (en) Antibodies against claudin 18.2 useful in cancer diagnosis
PT2426148E (pt) Anticorpo anti-rá-il-3 para se utilizar no tratamento de tumores do sangue
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
IL223604B (en) System for detection of an analyte in a body fluid
BRPI0806589A2 (pt) Catalisador, sua preparação e uso.
BRPI0911679A2 (pt) composto aciltiouréia, ou sal do mesmo, e seu uso
BRPI0821276A2 (pt) Produto, e, uso do produto
BR112012005208A2 (pt) antiocorpos contra o receptor de glucagon e seu uso
BRPI0718192A2 (pt) Corantes dispersos, sua preparação e seu uso.
BRPI1012924A2 (pt) derivados de amilóide p de soro e sua preparação e uso.
BRPI0816778A2 (pt) Sistema de infusão e transferência para uso com agentes radioativos
BR112012001797A2 (pt) composto bicíclico e uso do mesmo para propósitos médicos
IL230693A0 (en) Use of the i-3859 antibody for the detection and diagnosis of cancer
BRPI0810664A2 (pt) epítopo funcional de osteopontina, o anticorpo monoclonal anti-osteopontina e seu uso.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements